Replimune Group (NASDAQ:REPL) Stock Rating Upgraded by Wall Street Zen

Replimune Group (NASDAQ:REPL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other analysts have also recently commented on REPL. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a research note on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Leerink Partners boosted their price target on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Replimune Group Price Performance

Shares of Replimune Group stock opened at $17.61 on Friday. Replimune Group has a twelve month low of $1.50 and a twelve month high of $18.27. The company has a current ratio of 7.11, a quick ratio of 6.90 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -6.31 and a beta of 0.93. The business’s 50 day simple moving average is $13.58 and its 200-day simple moving average is $9.35.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. Equities research analysts forecast that Replimune Group will post -2.61 earnings per share for the current year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the transaction, the chief accounting officer owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. This represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock worth $1,038,364 in the last three months. 5.40% of the stock is owned by insiders.

Institutional Trading of Replimune Group

Several institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in Replimune Group in the third quarter worth approximately $64,000. Vise Technologies Inc. acquired a new position in shares of Replimune Group in the third quarter valued at approximately $163,000. China Universal Asset Management Co. Ltd. raised its holdings in Replimune Group by 30.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after purchasing an additional 4,050 shares in the last quarter. Maxi Investments CY Ltd purchased a new position in Replimune Group in the third quarter worth $556,000. Finally, Opaleye Management Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter valued at approximately $15,332,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.